Who makes HL140 20/10?

HL140 20/10 is developed by Hanlim Pharm. Co., Ltd..

Last reviewed 2026-04-23 · How we verify

HL140 20/10

Hanlim Pharm. Co., Ltd. · Phase 3 active Small molecule

HL140 20/10 is a fixed-dose combination product from Hanlim Pharm that combines two active pharmaceutical ingredients in a 20/10 mg ratio.

At a glance

Generic name	HL140 20/10
Sponsor	Hanlim Pharm. Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Without publicly available detailed information on HL140's specific molecular targets and mechanism of action, the exact pharmacological pathway cannot be definitively stated. The designation '20/10' indicates a fixed-dose combination of two components at those respective doses, currently in phase 3 clinical development.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HL140 20/10 CI brief — competitive landscape report
HL140 20/10 updates RSS · CI watch RSS
Hanlim Pharm. Co., Ltd. portfolio CI